Health TidingsOtsuka Study Suggests S-Equol May Help Women With Severe PMS and PMDD Otsuka Study Suggests S-Equol May Help Women With Severe PMS and PMDD Read Post »
Health TidingsNovel Oral HIV Capsid Inhibitor VH-499 Reduces Viral Load in Phase 2a Study Novel Oral HIV Capsid Inhibitor VH-499 Reduces Viral Load in Phase 2a Study Read Post »
Health TidingsTiziana Reports Third Phase 2 MSA Patient Shows Reduced Neuroinflammation o... Tiziana Reports Third Phase 2 MSA Patient Shows Reduced Neuroinflammation o... Read Post »
Health TidingsAbivax Advances Obefazimod Toward FDA NDA for Ulcerative Colitis Abivax Advances Obefazimod Toward FDA NDA for Ulcerative Colitis Read Post »
Health Tidings Mergers & AcquisitionsAbCellera, Vertex Sign Deal to Develop Autoimmune T-Cell Engagers AbCellera, Vertex Sign Deal to Develop Autoimmune T-Cell Engagers Read Post »
Health Tidings Mergers & AcquisitionsRelation, GSK Partner in $110M AI Drug Discovery Collaboration Relation, GSK Partner in $110M AI Drug Discovery Collaboration Read Post »
Health TidingsFDA Grants Priority Review to J&J’s Subcutaneous Amivantamab for ... FDA Grants Priority Review to J&J’s Subcutaneous Amivantamab for ... Read Post »
Health TidingsFDA Advisory Panel Recommends Against Deramiocel for DMD Cardiomyopathy FDA Advisory Panel Recommends Against Deramiocel for DMD Cardiomyopathy Read Post »
Health TidingsOmalizumab Outperformed Multiallergen Oral Immunotherapy in OUTMATCH Trial ... Omalizumab Outperformed Multiallergen Oral Immunotherapy in OUTMATCH Trial ... Read Post »
Health TidingsEyePoint Completes Enrollment in Phase 3 DURAVYU™ Trials for DME EyePoint Completes Enrollment in Phase 3 DURAVYU™ Trials for DME Read Post »
Health TidingsMHRA and NICE Approve Aficamten for Obstructive Hypertrophic Cardiomyopathy MHRA and NICE Approve Aficamten for Obstructive Hypertrophic Cardiomyopathy Read Post »
Health TidingsFDA Grants Priority Review to PolyPid’s D-PLEX100 for Surgical Site I... FDA Grants Priority Review to PolyPid’s D-PLEX100 for Surgical Site I... Read Post »
Health TidingsEuropean Commission Approves Opzelura for Adults with Moderate Atopic Derma... European Commission Approves Opzelura for Adults with Moderate Atopic Derma... Read Post »
Health TidingsFDA Grants Fast Track Designation to Insilico Medicine’s AI-Designed ... FDA Grants Fast Track Designation to Insilico Medicine’s AI-Designed ... Read Post »
Health TidingsOral Semaglutide Reduces Heavy Drinking in Phase 2 Trial, Supporting Furthe... Oral Semaglutide Reduces Heavy Drinking in Phase 2 Trial, Supporting Furthe... Read Post »
Health TidingsRepatha Wins CHMP Backing to Expand Cardiovascular Risk Reduction in High-R... Repatha Wins CHMP Backing to Expand Cardiovascular Risk Reduction in High-R... Read Post »
Health TidingsEuropean Commission Approves RINVOQ for Severe Alopecia Areata and Non-Segm... European Commission Approves RINVOQ for Severe Alopecia Areata and Non-Segm... Read Post »
Health TidingsFDA Raises Efficacy Concerns Over Replimune’s RP1 Before Advisory Com... FDA Raises Efficacy Concerns Over Replimune’s RP1 Before Advisory Com... Read Post »
Health TidingsLUCERNA Trial Evaluates New First-Line Combination for CLDN18.2-Positive Ga... LUCERNA Trial Evaluates New First-Line Combination for CLDN18.2-Positive Ga... Read Post »
Health TidingsFDA Grants Fast Track Designation to HAYA’s HTX-001 for nHCM FDA Grants Fast Track Designation to HAYA’s HTX-001 for nHCM Read Post »
Health TidingsREGENERA Shows Durable Benefits One Year After Lumpectomy REGENERA Shows Durable Benefits One Year After Lumpectomy Read Post »
Health TidingsOrganogenesis Publishes Positive Affinity Trial Results for Venous Leg Ulce... Organogenesis Publishes Positive Affinity Trial Results for Venous Leg Ulce... Read Post »
Health TidingsGSK’s Risvutatug Rezetecan Extends Progression-Free Survival in Phase III... GSK’s Risvutatug Rezetecan Extends Progression-Free Survival in Phase III... Read Post »
Health Tidings Mergers & AcquisitionsBioMarin, n-Lorem Advance First Mutation-Targeted Therapy for Newly Discove... BioMarin, n-Lorem Advance First Mutation-Targeted Therapy for Newly Discove... Read Post »
Health TidingsIDEAYA Starts IDE892 Phase 1/2 Expansion in MTAP-Deleted PDAC and NSCLC IDEAYA Starts IDE892 Phase 1/2 Expansion in MTAP-Deleted PDAC and NSCLC Read Post »
Health TidingsTwo-Drug Dovato Matches Three-Drug Biktarvy in Viral Suppression Trial Two-Drug Dovato Matches Three-Drug Biktarvy in Viral Suppression Trial Read Post »
Health TidingsFDA Clears Path for Gossamer’s Seralutinib NDA Submission in PAH FDA Clears Path for Gossamer’s Seralutinib NDA Submission in PAH Read Post »
Health Tidings Mergers & Acquisitionsargenx Adds First-in-Class FB102 Through $2.2B Forte Biosciences Acquisitio... argenx Adds First-in-Class FB102 Through $2.2B Forte Biosciences Acquisitio... Read Post »
Health TidingsMapLight Reports Positive Phase 2 Results for ML-007C-MA in Schizophrenia MapLight Reports Positive Phase 2 Results for ML-007C-MA in Schizophrenia Read Post »
Health TidingsInnoCare’s Fadeucravacitinib Meets Phase III Endpoint in Plaque Psori... InnoCare’s Fadeucravacitinib Meets Phase III Endpoint in Plaque Psori... Read Post »
Health Tidings Mergers & AcquisitionsYarrow Bioscience Initiates Phase 2 Trial of Anti-TSHR Antibody YB-101 for ... Yarrow Bioscience Initiates Phase 2 Trial of Anti-TSHR Antibody YB-101 for ... Read Post »
Health TidingsAmgen Defends TAVNEOS With New FDA Submission to Prevent Proposed U.S. Mark... Amgen Defends TAVNEOS With New FDA Submission to Prevent Proposed U.S. Mark... Read Post »
GenericsFDA Approves First OTC Tylenol with Naproxen for 12-Hour Pain Relief FDA Approves First OTC Tylenol with Naproxen for 12-Hour Pain Relief Read Post »
Health TidingsHEMGENIX Achieves 100 Commercial Treatments for Adults with Hemophilia B HEMGENIX Achieves 100 Commercial Treatments for Adults with Hemophilia B Read Post »
Health TidingsFDA Advisory Committee Recommends Four Peptides for 503A Compounding List D... FDA Advisory Committee Recommends Four Peptides for 503A Compounding List D... Read Post »
Health TidingsMerck Launches Global Access Plan for Once-Monthly HIV Prevention Pill Alim... Merck Launches Global Access Plan for Once-Monthly HIV Prevention Pill Alim... Read Post »
Health TidingsNanvuranlat Enters First-Line BTC Trial With New 46-Hour Infusion Strategy Nanvuranlat Enters First-Line BTC Trial With New 46-Hour Infusion Strategy Read Post »
Health TidingsFDA Grants Fast Track Status to Oral Orexin 2 Agonist Lu AH69593 for Narcol... FDA Grants Fast Track Status to Oral Orexin 2 Agonist Lu AH69593 for Narcol... Read Post »
Health TidingsInsilico Advances AI-Discovered Non-Opioid Pain Candidate ISM9528 Toward Cl... Insilico Advances AI-Discovered Non-Opioid Pain Candidate ISM9528 Toward Cl... Read Post »
Health TidingsTecvayli Plus Talvey Significantly Improves Survival in Phase 3 Multiple My... Tecvayli Plus Talvey Significantly Improves Survival in Phase 3 Multiple My... Read Post »
Health TidingsCrystalys Therapeutics Raises $130 Million to Advance Phase 3 Development o... Crystalys Therapeutics Raises $130 Million to Advance Phase 3 Development o... Read Post »
Health TidingsNHS England Introduces Fampridine for Walking Difficulties in Multiple Scle... NHS England Introduces Fampridine for Walking Difficulties in Multiple Scle... Read Post »
Health TidingsPositive TALAPRO-3 Data Earn FDA Priority Review for TALZENNA Plus XTANDI Positive TALAPRO-3 Data Earn FDA Priority Review for TALZENNA Plus XTANDI Read Post »
Health TidingsBridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 Read Post »
Health TidingsFDA Grants Orphan Drug Status to Affinia’s AFTX-201 for BAG3-Associat... FDA Grants Orphan Drug Status to Affinia’s AFTX-201 for BAG3-Associat... Read Post »
Health TidingsRadiopharm’s RAD101 PET Imaging Meets Phase 2b Primary Endpoint in Re... Radiopharm’s RAD101 PET Imaging Meets Phase 2b Primary Endpoint in Re... Read Post »
Health TidingsPeer-Reviewed Phase 1 Data Support TLX591-Tx as a Differentiated PSMA-Targe... Peer-Reviewed Phase 1 Data Support TLX591-Tx as a Differentiated PSMA-Targe... Read Post »
Health TidingsRibo’s Vortosiran Cuts Factor XI Activity by 92% in Phase 2a Coronary... Ribo’s Vortosiran Cuts Factor XI Activity by 92% in Phase 2a Coronary... Read Post »
GenericsFDA Expands Glenmark’s RYALTRIS Use for Seasonal Allergic Rhinitis in... FDA Expands Glenmark’s RYALTRIS Use for Seasonal Allergic Rhinitis in... Read Post »
Health TidingsIslatravir/Lenacapavir Maintains Virological Suppression Through 48 Weeks i... Islatravir/Lenacapavir Maintains Virological Suppression Through 48 Weeks i... Read Post »
